A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease

Neurology

Volumn 50, Issue 1, 1998, Pages 136-145

  Rogers, S L ^a   Farlow, M R ^b   Doody, R S ^c   Mohs, R ^d   Friedhoff, L T ^a  

^a EISAI INC   (United States)

^b INDIANA UNIVERSITY   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

^d MOUNT SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DONEPEZIL; PLACEBO;

ADULT; ALZHEIMER DISEASE; ARTICLE; CHOLINERGIC TRANSMISSION; CLINICAL TRIAL; COGNITION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; ENZYME INHIBITION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RATING SCALE;

EID: 0031883716     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.50.1.136     Document Type: Article

References (33)

1. Davies P, Maloney AJ. Selective loss of central cholinergic neurons in Alzheimer's disease. Lancet 1976;2:1403.
2. Perry EK, Perry RH, Blessed G, Tomlinson BE. Necropsy evidence of central cholinergic deficits in senile dementia [letter]. Lancet 1977;1:189.
3. Whitehouse PJ, Price DL, Clark AW, Coyle JT, DeLong MR. Alzheimer's disease: evidence for selective loss of cholinergic neurons in the nucleus basalis. Ann Neurol 1981;10:122-126.
4. Giacobini E, Becker R. Present progress and future development in the therapy for Alzheimer's disease. In: Iqbal K, Wisniewski HM, Winblad B, eds. Alzheimer's disease and related disorders. New York: Alan R Liss Inc., 1989:1121-1154.
5. Schneider LS, Farlow MR. Predicting response to cholinesterase inhibitors in Alzheimer's disease: possible approaches. CNS Drugs 1995;4:114-124.
6. Knapp MJ, Knopman DS, Solomon PR, Pendlebury WW, Davis CS, Gracon SI. For the Tacrine Study Group. A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. JAMA 1994;271:985-991.
7. Farlow M, Gracon SI, Hershey LA, Lewis, KW, Sadowsky CH, Dolan-Ureno J. A controlled trial of tacrine in Alzheimer's disease. JAMA 1992;268:2523-2529.
8. Hardiman S, Miller K, Murphy M. Clinical trials with velnacrine: (PROPP) The physician reference of predicted probabilities - a statistical model for the estimation of hepatotoxicity risk with velnacrine maleate. Acta Neurol Scand 1993; 149(suppl):46-52.
9. Antuono PG, for the Mentane Study Group. Effectiveness and safety of velnacrine for the treatment of Alzheimer's disease: a double-blind, placebo-controlled study. Arch Intern Med 1995; 155:1766-1772.
10. Rogers SL, Yaminishi Y, Yamatsu K. E2020 - the pharmacology of a piperidine cholinesterase inhibitor. In: Becker R, Giacobini E, eds. Cholinergic basis for Alzheimer therapy. Boston: Birkhäuser, 1991;314-320.
11. Rogers SL, Friedhoff LT, the Donepezil Study Group. The efficacy and safety of donepezil in patients with Alzheimer's disease: results of a US multicenter, randomized, double-blind, placebo-controlled trial. Dementia 1996;7:293-303.
12. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA work group under the auspices of Department of Health and Human Services task force in Alzheimer's disease. Neurology 1984;34:939-944.
13. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 3rd ed. Revised. Washington, DC: American Psychiatric Association, 1987.
14. Folstein NF, Folstein SE, McHugh PR. Mini-Mental State: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-198.
15. Hughes CD, Berg L, Danziger L, Coben LA, Martin RL. A new clinical scale for the staging of dementia. Br J Psychiatry 1982;140:566-572.
16. Rosen WG, Mohs RC, Davis K. A new rating scale for Alzheimer's disease. Am J Psychiatry 1984;141:1356-1364.
17. Schneider LS, Olin JT, Doody RS, et al. Validity and reliability of the Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change. AD Assoc Dis 1997;11(suppl 2):S22-32.
18. Blau TH. Quality of life, social indicators and criteria of change. Prof Psychol 1977;8:464-473.
19. Berg L, Miller JP, Baty J, Rubin EH, Morris JC, Figiel G. Mild senile dementia of the Alzheimer type. 4. Evaluation of intervention. Ann Neurol 1992;31:242-249.
20. Lee JW, Rogers SL, Friedhoff LT, Cooper NM. Validation and application of an HPLC method for the determination of 1-benzyl-4-[(5,6-dimethoxy-1-indanon)-2-yl] methyl piperidine HCl (E2020) in human plasma. Pharmaceutical Res 1992;9: S350.
21. Hulse JD, Rogers SL, Friedhoff LT, Sukovaty R, Pedersen JE, Lee JW. A radioenzyme assay of acetylcholinesterase activity in red blood cells and its correlation with 1-benzyl-4-[(5,6-dimethoxy-1-indanon)-2-yl] methyl piperidine HCI. Pharmaceutical Res 1992;9:S228.
22. Mohs RC, Davis BM, Johns CA, et al. Oral physostigmine treatment of patients with Alzheimer's disease. Am J Psychiatry 1985;142:28-33.
23. Stern, RG, Mohs RC, Davidson M, et al. A longitudinal study of Alzheimer's disease: measurement, rate and predictors of cognitive deterioration. Am J Psychiatry 1994;151:390-396.
24. Kramer-Ginsberg E, Mohs RC, Aryan M, et al. Clinical predictors of course of Alzheimer's patients in a longitudinal study: a preliminary report. Psychopharmacol Bull 1988;24:458-462.
25. Leber P. US Food and Drug Administration, Center for Drug Evaluation and Research, Division of Neuropharmacological Drug Products. Form and contents of NDA reviews: strategies for the efficacy analysis. November 5, 1985.
26. US Food and Drug Administration, Center for Drug Evaluation and Research, Office of Epidemiology and Biostatistics. COSTART: coding symbols for thesaurus of adverse reaction terms. 4th edition, 1993; Pub. PB93-209138.
27. Knopman D, Gracon S. Observations on the short-term "natural history" of probable Alzheimer's disease in a controlled clinical trial. Neurology 1994;44:260-265.
28. Thal LJ, Schwartz G, Sano M, et al. A multicenter double-blind study of controlled-release physostigmine for the treatment of symptoms secondary to Alzheimer's disease. Neurology 1996;47:1389-1395.
29. Canal N, Franceschi M, Italian Eptastigmine Investigators. Eptastigmine (MF-201). A double-blind, placebo-controlled clinical trial in Alzheimer's disease patients. In: Giacobini E, Becker R, eds. Alzheimer's disease: therapeutic strategies. Boston: Birkäuser, 1994; 108-112.
30. Peripheral and Central Nervous System Drugs Advisory Committee Meeting, July 7, 1989. Rockville MD: Dept of Health and Human Services, Public Health service, Food and Drug Administration; 1989:227.
31. Thai LJ, Maasur DM, Fuld PA, Sharpless NS, Davies P. Memory improvement with oral physostigmine and lecithin in Alzheimer's disease. In: Katzman R, ed. Banbury report: biological aspects of Alzheimer's disease. 9th ed. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press, 1983:461-470.
32. Becker R, Colliver J, Elble R, et al. Effects of metrifonate, a long acting cholinesterase inhibitor in Alzheimer's disease: report of an open trial. Drug Dev Res 1990;19:425-434.
33. Becker R. The second generation of cholinesterase inhibitors: clinical and pharmacological effects. In: Becker R, Giacobini E, eds. Cholinergic basis for Alzheimer therapy. Boston: Birkhäuser, 1991;263-296.